Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples